You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update

Version: N/A ID: 7-A-2018-2 jan 2020
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
Nasser H. Hanna, MD, Bryan J. Schneider, MD, Sarah Temin, MSPH, Sherman Baker Jr., MD, Julie Brahmer, MD, Peter M. Ellis, MD, PhD, Laurie E. Gaspar, MD, MBA, Rami Y. Haddad, MD, Paul J. Hesketh, MD, Dharamvir Jain, MD, Ishmael Jaiyesimi, MD, David H. Johnson, MD, Natasha B. Leighl, MD, Tanyanika Phillips, MD, Gregory J. Riely, MD, PhD, Andrew G. Robinson, MD, Rafael Rosell, MD, Joan H. Schiller, MD, Navneet Singh, MD, DM, David R. Spigel, MD, Janis O. Stabler, MD, Joan Tashbar, MD, and Gregory Masters, MD

Guideline Objective:

This clinical practice guideline was produced jointly by the American Society of Clinical Oncology (ASCO) and Ontario Health (Cancer Care Ontario) (OH CCO). The aim of this work is to provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) without driver alterations. A guideline update for patients with stage IV NSCLC with driver alterations will be published separately. The joint guideline is published in the Journal of Clinical Oncology (JCO) and can be accessed directly from the link "Full Report” below. Due to rapidly evolving evidence on this topic, ASCO has updated this guidance as a Living Guideline. For updated recommendations, visit Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations Living Guideline. 

Patient Population:

Patients with stage IV NSCLC without driver alterations in epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) (with known EGFR and ALK) status (plus programmed death ligand 1 (PD-L1) tumor proportion score (TPS) test results available to the clinician being optimal).*

Intended Guideline Users:

Oncology care providers (including primary care physicians, specialists, nurses, social workers, and any other relevant member of a comprehensive multidisciplinary cancer care team), patients, and their caregivers in North America and beyond.

Research Question(s)

What systemic therapy treatment options should be offered to patients with stage IV non–small-cell lung cancer (NSCLC) without driver alterations, depending on the subtype of the patient’s cancer?

pdf download Summary (PDF) (476.62 Ko)
pdf download Full Report (PDF) (741.05 Ko)